German Lozano Guzman, MD
Pediatric Nephrology · Philadelphia, PANPI 1558660423
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (54.6%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. AstraZeneca accounts for 96.9% of it on its own, with 16 other manufacturers making up the rest. Reporting peaked in 2024 at $26,021 and has fallen 90.2% since, to $2,543 in 2025. Among pediatric nephrology clinicians in PA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 165 payments — averaging $459.30 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$73K
- Aurinia Pharma U.S., Inc.$755
- Travere Therapeutics, Inc.$349
- Novo Nordisk$213
- Kaneka Medical America LLC$163
- Leadiant Biosciences, Inc.$142
- plus $691 from 11 others
What the payments were for
- Consulting fees$41,36055%
- Speaking & faculty fees$22,76030%
- Travel & lodging$6,5369%
- Food & beverage$4,8696%
- Education$970%
- Entertainment$1630%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca | 107 | $73,473 |
| Aurinia Pharma U.S., Inc. | 17 | $755 |
| Travere Therapeutics, Inc. | 8 | $349 |
| Novo Nordisk | 5 | $213 |
| Kaneka Medical America LLC | 1 | $163 |
| Leadiant Biosciences, Inc. | 5 | $142 |
| GSK | 2 | $141 |
| Rhythm Pharmaceuticals, Inc. | 1 | $124 |
| Alnylam Pharmaceuticals Inc. | 5 | $107 |
| Calliditas Therapeutics US Inc. | 3 | $62 |
| Takeda Pharmaceuticals U.S.A., Inc. | 2 | $61 |
| Potrero Medical, Inc. | 1 | $45 |
| Amgen | 2 | $43 |
| Baxter Healthcare | 2 | $38 |
| Recordati_rare_diseases_inc. | 2 | $36 |
| Ultragenyx Pharmaceutical Inc. | 1 | $19 |
| Biomarin Pharmaceutical Inc. | 1 | $16 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$75,785 in reported general payments places this provider in the 95th percentile of 32 pediatric nephrology providers in Pennsylvania.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| KaterziaAmlodipine Benzoate | 14 | $13,780 |
| Famotidine | 20 | $1,259 |
| Fluconazole | 17 | $535 |
| Prednisolone Sodium Phosphate | 29 | $141 |
Paid to pharmacies, not to this prescriber.
Other pediatric nephrology in Philadelphia
- Christine SethnaPhiladelphia$17K
- Sandra AmaralPhiladelphia$14K
- Susan FurthPhiladelphia$13K
- Samina MuneeruddinPhiladelphia$5K
- Anil MongiaPhiladelphia$4K
- Kevin MeyersPhiladelphia$4K
- Christopher LarosaPhiladelphia$2K
- Selasie GokaPhiladelphia$2K
- Susan ConleyPhiladelphia$1K
- Lawrence CopelovitchPhiladelphia$950
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.